Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study

Yingzhen Du(National Clinical Research), Lei Tu(Wuhan Union Hospital), Pingjun Zhu(National Clinical Research), Mi Mu(National Clinical Research), Runsheng Wang(National Clinical Research), Pengcheng Yang(Wuhan University), Xi Wang(National Clinical Research), Chao Hu(Chinese PLA General Hospital), Rongyu Ping(Chinese PLA General Hospital), Peng Hu(Chinese PLA General Hospital), Tianzhi Li(Chinese PLA General Hospital), Feng Cao(Chinese PLA General Hospital), Christopher Chang(Joe DiMaggio Children's Hospital), Qinyong Hu(Wuhan University), Yang Jin(Wuhan Union Hospital), Guogang Xu(Chinese PLA General Hospital)
American Journal of Respiratory and Critical Care Medicine
April 3, 2020
Cited by 990Open Access
Full Text

Abstract

Abstract Rationale The global death toll from coronavirus disease (COVID-19) virus as of May 12, 2020, exceeds 286,000. The risk factors for death were attributed to advanced age and comorbidities but have not been accurately defined. Objectives To report the clinical features of 85 fatal cases of COVID-19 in two hospitals in Wuhan. Methods Medical records were collected of 85 fatal cases of COVID-19 between January 9, 2020, and February 15, 2020. Information recorded included medical history, exposure history, comorbidities, symptoms, signs, laboratory findings, computed tomographic scans, and clinical management. Measurements and Main Results The median age of the patients was 65.8 years, and 72.9% were male. Common symptoms were fever (78 [91.8%]), shortness of breath (50 [58.8%]), fatigue (50 [58.8%]), and dyspnea (60 [70.6%]). Hypertension, diabetes, and coronary heart disease were the most common comorbidities. Notably, 81.2% of patients had very low eosinophil counts on admission. Complications included respiratory failure (80 [94.1%]), shock (69 [81.2%]), acute respiratory distress syndrome (63 [74.1%]), and arrhythmia (51 [60%]), among others. Most patients received antibiotic (77 [90.6%]), antiviral (78 [91.8%]), and glucocorticoid (65 [76.5%]) treatments. A total of 38 (44.7%) and 33 (38.8%) patients received intravenous immunoglobulin and IFN-α2b, respectively. Conclusions In this depictive study of 85 fatal cases of COVID-19, most cases were males aged over 50 years with noncommunicable chronic diseases. The majority of the patients died of multiple organ failure. Early onset of shortness of breath may be used as an observational symptom for COVID-19 exacerbations. Eosinophilopenia may indicate a poor prognosis. A combination of antimicrobial drugs did not offer considerable benefit to the outcome of this group of patients.


Related Papers

No related papers found

Powered by citation graph analysis